Chinese biotech Longbio Pharma Co. Ltd. announced its IPO on the Hong Kong Stock Exchange to raise HK$1.362 billion (US$174 million) to progress its lead candidate, LP-003, a next-generation anti-IgE antibody.
Protuoso Biosciences has announced the close of an oversubscribed $9.5 million seed financing round, the proceeds of which will be used to advance its multifunctional protein engineering platform and broad pipeline across cardiometabolic, oncology and autoimmune diseases.
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that autoimmunity might underlie the persistent neurological symptoms seen in long COVID, researchers at Yale University and Mount Sinai now reinforce this hypothesis. SARS-CoV-2 infection appears to trigger an autoimmune mechanism that drives chronic pain, fatigue and cognitive impairment in some patients.
Cell therapy based on fibroblasts has shown promise in the treatment of psoriasis due to immune modulation capability and strong expansion when cultured. Work at Fibrobiologics Inc. has focused on the impact of culture format and donors of human dermal fibroblasts (HDFs) on the therapeutic efficacy and immune responses in murine models of psoriasis.
Although influenza virus infection can be particularly life-threatening among young infants, approved vaccines are lacking for infants under 6 months. Aiming to overcome the required annual updates to the influenza vaccine, recent efforts have focused on generating vaccines that promote broadly reactive antibodies (Abs) targeting conserved regions of viral proteins, such as the stem domain of hemagglutinin (HA).
Biotle has received a clinical trial notice from China’s National Medical Products Administration (NMPA) for its IND application for BTL-203, the company’s bispecific FcRn inhibitor being developed for the treatment of multiple autoimmune diseases.
Nextgen Bioscience Co. Ltd. has identified new sphingosine 1-phosphate S1P1 and S1P4 receptor antagonists potentially useful for the treatment of autoimmune diseases, ulcerative colitis and Crohn’s disease.
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.
Hangzhou Qihan Biotech Co. Ltd. has obtained IND clearance from the FDA for QT-019C, a universal allogeneic CAR T-cell therapy for autoimmune diseases. QT-019C cell injection is an off-the-shelf allogeneic CAR T-cell therapy engineered from healthy donor leukapheresis products to stably express two distinct CARs targeting CD19 and BCMA.
Shares of Immunovant Inc. (NASDAQ:IMVT) gained 35% after the firm disclosed early but “compelling” data from a phase IIb study testing next-generation FcRn inhibitor IMVT-1402 in patients with difficult-to-treat rheumatoid arthritis (D2T RA), including those whose disease has persisted despite treatment with TNF and JAK inhibitors.
RSS
